ADCT - LOTIS-7 Data Presentation at EHA2025
Jun 14, 2025, 10:30:00 AM UTC
Summary
ADC Therapeutics will present updated data from the LOTIS-7 trial during a poster session on June 14, 2025, at the EHA2025 Congress in Milan, Italy. The trial evaluates the efficacy of ZYNLONTA in combination with glofitamab for patients with relapsed/refractory DLBCL, showing promising results with an overall response rate of 95.5%.
Company
ADC THERAPEUTICS SA (ADCT)NYSE — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.adctherapeutics.comSimilar Events
LOTIS-7 Phase 1b Trial Data Update
Initial data from the LOTIS-7 trial of ZYNLONTA plus glofitamab showed a 94% best ORR and 72% CR rate, with a data update expected in Q2 2025.
clinical readoutLOTIS-5 Phase 3 Trial Data Update
Enrollment in the LOTIS-5 Phase 3 trial of ZYNLONTA plus rituximab is complete, with a data update anticipated in late 2025 after PFS events.
clinical readoutLOTIS-5 Trial Topline Results
ADC Therapeutics anticipates sharing topline results of the LOTIS-5 trial's primary endpoint analysis by the end of 2025, which may support a supplemental BLA submission in Q1 2026.
clinical readoutPresentation of MZL Data at ICML
ADC Therapeutics will present data on marginal zone lymphoma at the International Conference on Malignant Lymphoma (ICML) from June 17-21, 2025, in Lugano, Switzerland. The presentation will include findings from a phase 2 study of loncastuximab in patients with relapsed/refractory marginal zone lymphoma, highlighting its potential efficacy in this patient population.
clinical readout